Reduced In Vitro Activity of Ceftaroline by Etest among Clonal Complex 239 Methicillin-Resistant Staphylococcus aureus Clinical Strains from Australia

Antimicrob Agents Chemother. 2015 Dec;59(12):7837-41. doi: 10.1128/AAC.02015-15. Epub 2015 Sep 21.

Abstract

A total of 421 methicillin-resistant Staphylococcus aureus (MRSA) clinical isolates were tested for ceftaroline susceptibility by Etest (bioMérieux). A multidrug resistant phenotype was found in 40.9%, and clonal complex 239 (CC239) was found in 33.5%. Ceftaroline nonsusceptibility (MIC, >1.0 μg/ml) was 16.9% overall. Nonsusceptibility was significantly higher in CC239 (41.1%, 58/141) and in isolates with a multidrug resistant phenotype (35.5%, 61/172) compared with comparators (P < 0.0001). Nonsusceptibility of common multidrug resistant MRSA clones limits the empirical use of ceftaroline for these infections.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Australia
  • Ceftaroline
  • Cephalosporins / pharmacology*
  • Clone Cells
  • Drug Resistance, Multiple, Bacterial*
  • Humans
  • Methicillin / pharmacology
  • Methicillin-Resistant Staphylococcus aureus / drug effects*
  • Methicillin-Resistant Staphylococcus aureus / growth & development
  • Methicillin-Resistant Staphylococcus aureus / isolation & purification
  • Microbial Sensitivity Tests
  • Phenotype
  • Staphylococcal Infections / drug therapy
  • Staphylococcal Infections / microbiology

Substances

  • Anti-Bacterial Agents
  • Cephalosporins
  • Methicillin